WO2000071154A3 - Stability, biocompatibility optimized adjuvant (sba) for enhancing humoral and cellular immune response - Google Patents

Stability, biocompatibility optimized adjuvant (sba) for enhancing humoral and cellular immune response Download PDF

Info

Publication number
WO2000071154A3
WO2000071154A3 PCT/EP2000/004565 EP0004565W WO0071154A3 WO 2000071154 A3 WO2000071154 A3 WO 2000071154A3 EP 0004565 W EP0004565 W EP 0004565W WO 0071154 A3 WO0071154 A3 WO 0071154A3
Authority
WO
WIPO (PCT)
Prior art keywords
sba
immune response
adjuvant
cellular immune
biocompatibility
Prior art date
Application number
PCT/EP2000/004565
Other languages
German (de)
French (fr)
Other versions
WO2000071154A2 (en
Inventor
Rainer Helmut Mueller
Nikolaus Grubhofer
Carsten Olbrich
Original Assignee
Pharmasol Gmbh
Rainer Helmut Mueller
Nikolaus Grubhofer
Carsten Olbrich
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmasol Gmbh, Rainer Helmut Mueller, Nikolaus Grubhofer, Carsten Olbrich filed Critical Pharmasol Gmbh
Priority to AU52142/00A priority Critical patent/AU5214200A/en
Priority to BR0010823-5A priority patent/BR0010823A/en
Priority to JP2000619456A priority patent/JP2003500365A/en
Priority to EP00936761A priority patent/EP1183045A2/en
Priority to KR1020017014653A priority patent/KR20020012221A/en
Priority to CA002373239A priority patent/CA2373239A1/en
Priority to MXPA01011660A priority patent/MXPA01011660A/en
Publication of WO2000071154A2 publication Critical patent/WO2000071154A2/en
Publication of WO2000071154A3 publication Critical patent/WO2000071154A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants

Abstract

The invention relates to a stability and biocompatibility-optimized adjuvant (SBA) for enhancing the humoral and cellular immune response by jointly injecting said adjuvant with one or more antigens. The adjuvant consists of particles based on solid lipids or solid lipid mixtures and can be used in the production of more efficient and compatible vaccines, the inoculation of human beings and animals and for obtaining antibodies. The strength of the immune response can be modulated in a targeted manner and additionally adapted to the specific species by selecting the size, charge and surface characteristics of the particles. Other adjuvants, e.g. molecular adjuvants such as GMDP, can be added to the SBA, whereby the cellular immune response is additionally enhanced. The SBA is more effective and cost-efficient and easier to use than existing products and is well tolerated in vivo.
PCT/EP2000/004565 1999-05-20 2000-05-19 Stability, biocompatibility optimized adjuvant (sba) for enhancing humoral and cellular immune response WO2000071154A2 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
AU52142/00A AU5214200A (en) 1999-05-20 2000-05-19 Stability, biocompatibility optimized adjuvant (sba) for enhancing humoral and cellular immune response
BR0010823-5A BR0010823A (en) 1999-05-20 2000-05-19 Stability adjuvant, optimized biocompatibility (sba) to enhance the humoral and cellular immune response
JP2000619456A JP2003500365A (en) 1999-05-20 2000-05-19 Stability, biocompatibility optimized adjuvant (SBA) to enhance humoral and cellular immune responses
EP00936761A EP1183045A2 (en) 1999-05-20 2000-05-19 Stability, biocompatibility optimized adjuvant (sba) for enhancing humoral and cellular immune response
KR1020017014653A KR20020012221A (en) 1999-05-20 2000-05-19 Stability, biocompatibility optimized adjuvant(sba) for enhancing humoral and cellular immune response
CA002373239A CA2373239A1 (en) 1999-05-20 2000-05-19 Stability, biocompatibility optimized adjuvant (sba) for enhancing humoral and cellular immune response
MXPA01011660A MXPA01011660A (en) 1999-05-20 2000-05-19 Stability, biocompatibility optimized adjuvant (sba) for enhancing humoral and cellular immune response.

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19923256 1999-05-20
DE19923256.3 1999-05-20

Publications (2)

Publication Number Publication Date
WO2000071154A2 WO2000071154A2 (en) 2000-11-30
WO2000071154A3 true WO2000071154A3 (en) 2001-06-28

Family

ID=7908697

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/EP2000/004565 WO2000071154A2 (en) 1999-05-20 2000-05-19 Stability, biocompatibility optimized adjuvant (sba) for enhancing humoral and cellular immune response
PCT/EP2000/004644 WO2000071077A2 (en) 1999-05-20 2000-05-22 Adjuvant which is optimized with regard to stability and biocompatibility (sba) and which is provided for increasing the humoral and cellular immune response

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/EP2000/004644 WO2000071077A2 (en) 1999-05-20 2000-05-22 Adjuvant which is optimized with regard to stability and biocompatibility (sba) and which is provided for increasing the humoral and cellular immune response

Country Status (11)

Country Link
EP (1) EP1183045A2 (en)
JP (1) JP2003500365A (en)
KR (1) KR20020012221A (en)
AU (2) AU5214200A (en)
BR (1) BR0010823A (en)
CA (1) CA2373239A1 (en)
DE (1) DE10024788A1 (en)
MX (1) MXPA01011660A (en)
TR (1) TR200103333T2 (en)
WO (2) WO2000071154A2 (en)
ZA (1) ZA200109147B (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9241903B2 (en) 2006-02-22 2016-01-26 Mannkind Corporation Method for improving the pharmaceutic properties of microparticles comprising diketopiperazine and an active agent

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003500365A (en) * 1999-05-20 2003-01-07 ファルマソル ゲーエムベーハー Stability, biocompatibility optimized adjuvant (SBA) to enhance humoral and cellular immune responses
US9006175B2 (en) 1999-06-29 2015-04-14 Mannkind Corporation Potentiation of glucose elimination
WO2003080149A2 (en) 2002-03-20 2003-10-02 Mannkind Corporation Inhalation apparatus
ATE545434T1 (en) * 2003-10-23 2012-03-15 Novartis Vaccines & Diagnostic STABILIZED COMPOSITIONS
FR2873386B1 (en) 2004-07-22 2011-01-14 Agence Francaise De Securite Sanitaire Des Aliments Afssa VACCINE COMPOSITION AGAINST RHODOCOCCUS EQUI
JP5078014B2 (en) 2004-08-20 2012-11-21 マンカインド コーポレイション Catalytic reaction of diketopiperazine synthesis.
HUE026797T2 (en) 2004-08-23 2016-07-28 Mannkind Corp Diketopiperazine salts for drug delivery
KR20120060245A (en) 2005-09-14 2012-06-11 맨카인드 코포레이션 Method of drug formulation based on increasing the affinity of crystalline microparticle surfaces for active agents
EP3281663B8 (en) 2008-06-13 2022-09-21 MannKind Corporation Breath powered dry powder inhaler for drug delivery
US8485180B2 (en) 2008-06-13 2013-07-16 Mannkind Corporation Dry powder drug delivery system
US9364619B2 (en) 2008-06-20 2016-06-14 Mannkind Corporation Interactive apparatus and method for real-time profiling of inhalation efforts
TWI494123B (en) 2008-08-11 2015-08-01 Mannkind Corp Use of ultrarapid acting insulin
US8314106B2 (en) 2008-12-29 2012-11-20 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
CA2754595C (en) 2009-03-11 2017-06-27 Mannkind Corporation Apparatus, system and method for measuring resistance of an inhaler
WO2010144789A2 (en) 2009-06-12 2010-12-16 Mannkind Corporation Diketopiperazine microparticles with defined specific surface areas
CA2778698A1 (en) 2009-11-03 2011-05-12 Mannkind Corporation An apparatus and method for simulating inhalation efforts
AU2011271097B2 (en) 2010-06-21 2014-11-27 Mannkind Corporation Dry powder drug delivery system and methods
CN105667994B (en) 2011-04-01 2018-04-06 曼金德公司 Blister package for pharmaceutical kit
WO2012174472A1 (en) 2011-06-17 2012-12-20 Mannkind Corporation High capacity diketopiperazine microparticles
KR20140095483A (en) 2011-10-24 2014-08-01 맨카인드 코포레이션 Methods and compositions for treating pain
EP2844195B1 (en) 2012-04-30 2019-03-20 Össur HF Prosthetic device, system and method for increasing vacuum attachment
DK2872205T3 (en) 2012-07-12 2017-02-27 Mannkind Corp DRY POWDER FORMAL ADMINISTRATION SYSTEM
WO2014066856A1 (en) 2012-10-26 2014-05-01 Mannkind Corporation Inhalable influenza vaccine compositions and methods
KR102499439B1 (en) 2013-03-15 2023-02-13 맨카인드 코포레이션 Microcrystalline diketopiperazine compositions and methods
WO2015010092A1 (en) 2013-07-18 2015-01-22 Mannkind Corporation Heat-stable dry powder pharmaceutical compositions and methods
JP2016530930A (en) 2013-08-05 2016-10-06 マンカインド コーポレイション Ventilation device and method
WO2015148905A1 (en) 2014-03-28 2015-10-01 Mannkind Corporation Use of ultrarapid acting insulin
US10561806B2 (en) 2014-10-02 2020-02-18 Mannkind Corporation Mouthpiece cover for an inhaler
EP3386540A1 (en) * 2015-12-08 2018-10-17 GlaxoSmithKline Biologicals S.A. Novel adjuvant formulations

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19745950A1 (en) * 1997-10-17 1999-04-22 Dds Drug Delivery Service Ges Drug carrier particle for site specific drug delivery, especially to CNS
WO2000006120A1 (en) * 1998-07-31 2000-02-10 Korea Institute Of Science And Technology Lipid emulsion and solid lipid nanoparticle as a gene or drug carrier
DE10024788A1 (en) * 1999-05-20 2000-11-23 Gerbu Gmbh Substance for increasing an immune response during vaccinations or for increasing the production of antibodies, comprises solid lipid particles of a specific size and charge

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19745950A1 (en) * 1997-10-17 1999-04-22 Dds Drug Delivery Service Ges Drug carrier particle for site specific drug delivery, especially to CNS
WO2000006120A1 (en) * 1998-07-31 2000-02-10 Korea Institute Of Science And Technology Lipid emulsion and solid lipid nanoparticle as a gene or drug carrier
DE10024788A1 (en) * 1999-05-20 2000-11-23 Gerbu Gmbh Substance for increasing an immune response during vaccinations or for increasing the production of antibodies, comprises solid lipid particles of a specific size and charge

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
DATABASE CHEMABS [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; OLBRICH, C. ET AL: "Solid lipid nanoparticles (SLN) as vaccine adjuvant - study in sheep with a mycoplasma bovis antigen and stability testing", XP002155569, retrieved from STN *
HILGERS L A ET AL: "A novel non-mineral oil-based adjuvant. I. Efficacy of a synthetic sulfolipopolysaccharide in a squalane-in-water emulsion in laboratory animals.", VACCINE, (1994 MAY) 12 (7) 653-60., XP002155567 *
MULLER R H ET AL: "Solid lipid nanoparticles (SLN) as potential carrier for human use: interaction with human granulocytes", JOURNAL OF CONTROLLED RELEASE,NL,ELSEVIER SCIENCE PUBLISHERS B.V. AMSTERDAM, vol. 47, no. 3, 8 September 1997 (1997-09-08), pages 261 - 269, XP004125818, ISSN: 0168-3659 *
PROC. INT. SYMP. CONTROLLED RELEASE BIOACT. MATER. (2000), 27TH, 293-294 *
SCHOLER N. ET AL: "Effect of solid lipid nanoparticles (SLN) on cytokine production and the viability of murine peritoneal macrophages.", JOURNAL OF MICROENCAPSULATION, (2000) 17/5 (639-650)., XP002155568 *
ZUR MUHLEN A ET AL: "Solid lipid nanoparticles (SLN) for controlled drug delivery--drug release and release mechanism.", EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, (1998 MAR) 45 (2) 149-55., XP000738298 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9241903B2 (en) 2006-02-22 2016-01-26 Mannkind Corporation Method for improving the pharmaceutic properties of microparticles comprising diketopiperazine and an active agent

Also Published As

Publication number Publication date
EP1183045A2 (en) 2002-03-06
AU5214200A (en) 2000-12-12
WO2000071077A2 (en) 2000-11-30
ZA200109147B (en) 2002-05-08
JP2003500365A (en) 2003-01-07
CA2373239A1 (en) 2000-11-30
MXPA01011660A (en) 2004-04-05
TR200103333T2 (en) 2002-04-22
AU5809100A (en) 2000-12-12
DE10024788A1 (en) 2000-11-23
KR20020012221A (en) 2002-02-15
BR0010823A (en) 2002-03-05
WO2000071154A2 (en) 2000-11-30

Similar Documents

Publication Publication Date Title
WO2000071154A3 (en) Stability, biocompatibility optimized adjuvant (sba) for enhancing humoral and cellular immune response
WO2003059381A3 (en) Immunogenic preparations and vaccines on the basis of mrna
EP1333858B8 (en) Vaccines with enhanced immune response and methods for their preparation
WO1999041369A3 (en) Genetic vaccine vector engineering
EP1955709A3 (en) Adjuvant compositions for enhancing immune responses to polynucleotide-based vaccines
IL150602A0 (en) Proteosome influenza vaccine
WO2003024480A3 (en) In vivo activation of antigen presenting cells for enhancement of immune responses induced by virus like particles
WO2000056360A3 (en) Vaccine against antigens from bacteriae
EP1964573A3 (en) Method of inducing and/or enhancing an immune response to tumor antigens
WO2000050006A3 (en) Microemulsions with adsorbed macromoelecules and microparticles
WO2002034205A3 (en) Using heat shock proteins to increase immune response
WO1999040936A3 (en) Pneumococcal and meningococcal vaccines formulated with interleukin-12
IL145982A0 (en) Vaccines
HK1067058A1 (en) Packaging of immunostimulatory cpg into virus-like particles: method of preparation and use
IS4518A (en) New vaccine formulation
IL154913A0 (en) Composition comprising immunogenic microparticles
WO2003039595A3 (en) Mucosal adjuvants comprising an oligonucleotide and a cationic lipid
CA2272338A1 (en) Immunization of infants
WO2007008918A3 (en) Virus vaccines comprising envelope-bound immunomodulatory proteins and methods of use thereof
WO2001062283A3 (en) Mucosal adjuvant formulation
WO2002009752A3 (en) Immunological adjuvant compounds
WO2002076485A3 (en) Vaccine for modulating between t1 and t2 immune responses
WO2003083083A3 (en) Methods of using flt3-ligand in immunization protocols
WO2000006198A3 (en) Adjuvant comprising pulmonary surfactant
WO1997047271A3 (en) Cellular vaccines and immunotherapeutics and methods for their preparation

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2001/09147

Country of ref document: ZA

Ref document number: 200109147

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: PA/a/2001/011660

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 515530

Country of ref document: NZ

Ref document number: 1020017014653

Country of ref document: KR

ENP Entry into the national phase

Ref document number: 2373239

Country of ref document: CA

Ref document number: 2373239

Country of ref document: CA

Kind code of ref document: A

Ref document number: 2000 619456

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2001/03333

Country of ref document: TR

WWE Wipo information: entry into national phase

Ref document number: 52142/00

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2000936761

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1020017014653

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2000936761

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 09959927

Country of ref document: US

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 1020017014653

Country of ref document: KR

WWW Wipo information: withdrawn in national office

Ref document number: 2000936761

Country of ref document: EP